Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 103Lymphoma, Large B-Cell, Diffuse 80Leukemia, Myeloid, Acute 74Multiple Myeloma 70Breast Neoplasms 69Lymphoma, Non-Hodgkin 62Lymphoma 61Leukemia, Lymphocytic, Chronic, B-Cell 53Burkitt Lymphoma 53Recurrence 51Lymphoma, Follicular 51Myelodysplastic Syndromes 50Lymphoma, B-Cell 47Leukemia 43Triple Negative Breast Neoplasms 40Lymphoma, Mantle-Cell 38Neoplasms 37Hodgkin Disease 34Melanoma 33Lymphoma, B-Cell, Marginal Zone 32Hematologic Neoplasms 31Leukemia, Myelogenous, Chronic, BCR-ABL Positive 29Neuroblastoma 28Ovarian Neoplasms 26Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 23Neoplasm Metastasis 22Leukemia, Biphenotypic, Acute 22Pancreatic Neoplasms 21Sarcoma 18Myeloproliferative Disorders 17

Interventions

Trastuzumab 15pertuzumab 10Docetaxel 7Paclitaxel 5tucatinib 4pyrotinib 4Capecitabine 4Carboplatin 2Ado-Trastuzumab Emtansine 2trastuzumab deruxtecan 1pegfilgrastim 1exemestane 1dalpiciclib 1atezolizumab 1Protons 1Neoadjuvant Therapy 1Leuprolide 1Isovaleryl-CoA Dehydrogenase 1Injections 1Goserelin 1Genetic Testing 1Fulvestrant 1Fluorodeoxyglucose F18 1Cyclophosphamide 1Blood Specimen Collection 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × Cyclophosphamide × 1 year × Clear all
NCT07635342 2026-06-09

Pyrotinib Plus Trastuzumab and Chemotherapy for HER2-Positive Early Breast Cancer

Hebei Medical University Fourth Hospital

Phase 2 Recruiting
182 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡